Cell Prolif. 2017 Oct;50(5). doi: 10.1111/cpr.12366. Epub 2017 Aug 1.
2017-10-07Cell Prolif. 2017 Oct;50(5). doi: 10.1111/cpr.12366. Epub 2017 Aug 1.
Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.